The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.

Boston Scientific forked over $175 million up front for Apama Medical, which is working on a new treatment for afib.

Illumina Ventures reeled in $130 million in new funding, bringing its genomics-ventured fund to $230 million.

AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.

The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.

A team of researchers led by Princeton University has published genetic data related to 44 different human tissue types.

After posting positive results from a midstage test of its oral immunotherapy AR101 last spring, Aimmune Therapeutics will try out its peanut allergy…

The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.

Incyte and Bristol-Myers Squibb/Flexus are set to go to war in the courts over claims that a former scientist stole info around an oncology med.

Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.